Filing Analysis
Tvardi Therapeutics, Inc. filed an 8-K to announce its financial results and business highlights for the fiscal quarter ended June 30, 2026.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Fiscal quarter ended June 30, 2026.
- Announcement date: August 14, 2026.
Tvardi Therapeutics, Inc. issued a press release announcing the selection of Ulcerative Colitis as the initial indication for its TTI-109 program and released an updated corporate presentation.
📋 Key Facts
- Company selected Ulcerative Colitis as the initial clinical indication for TTI-109 on July 30, 2026.
- Released an updated corporate presentation to provide current company information.
Tvardi Therapeutics, Inc. has amended its existing at-the-market (ATM) offering program to increase the capacity for issuing common stock by an additional $9,689,765.
🚩 Red Flags
- Continued reliance on ATM offerings to raise capital suggests ongoing cash burn or liquidity needs typical of micro-cap biotech firms.
- Subject to 'baby shelf' rules, which limits the speed and volume at which the company can access capital markets.
📋 Key Facts
- Increased ATM offering capacity by $9,689,765 via a prospectus supplement filed on July 17, 2026.
- The original Sales Agreement with JonesTrading Institutional Services LLC (dated May 1, 2026) allowed for up to $12.5 million in aggregate offerings.
- In the prior 12-month period, the company sold 3,110,769 shares for approximately $11.0 million in gross proceeds.
- The company is subject to 'baby shelf' rules (General Instruction I.B.6) due to a non-affiliate market value of $62,208,945.
- Shares are being issued under an existing S-3 registration statement (File No. 333-295496).
Tvardi Therapeutics, Inc. issued a press release and updated corporate presentation regarding clinical updates for its TTI-109 Phase 1 study. The update focuses on prodrug design, tolerability, and pharmacodynamic evidence of STAT3 target engagement.
📋 Key Facts
- Released clinical updates for TTI-109 Phase 1 Study on July 7, 2026.
- Study results confirm prodrug design and improved tolerability.
- Data provides pharmacodynamic evidence of STAT3 target engagement.
- Company released an updated corporate presentation to accompany the clinical data.
Tvardi Therapeutics reported the results of its Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected three Class II directors, approved executive compensation, set the frequency of compensation votes to one year, and ratified Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Election of Class II directors: Imran Alibhai, Ph.D., Cynthia Smith, and Sujal Shah were elected to serve until the 2029 Annual Meeting.
- Executive compensation was approved on a non-binding advisory basis (3,482,265 votes For vs 161,795 Against).
- Stockholders voted for a 1-year frequency for advisory votes on executive compensation (3,453,729 votes).
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Tvardi Therapeutics, Inc. announced its financial results and business highlights for the fiscal quarter ended March 31, 2026. The disclosure was made via a press release furnished with the SEC on May 8, 2026.
📋 Key Facts
- The filing reports financial results for the first quarter of 2026.
- The press release was issued on May 8, 2026.
- The information is furnished under Item 2.02 and is not considered 'filed' for statutory liability purposes.
- The filing includes Exhibit 99.1, which contains the full text of the earnings press release.
Tvardi Therapeutics, Inc. announced its financial results and business highlights for the fiscal quarter and year ended December 31, 2025. The report was furnished under Item 2.02 and includes a press release as an exhibit.
📋 Key Facts
- The filing was made on March 31, 2026, reporting on the period ended December 31, 2025.
- The company reported under Item 2.02 (Results of Operations and Financial Condition).
- The report includes Exhibit 99.1, which is the press release detailing financial performance.
- The filing was signed by CEO Imran Alibhai.
Tvardi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026. The filing outlines the specific deadlines for stockholders to submit proposals and director nominations for consideration at the meeting.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is set for June 9, 2026.
- Stockholder proposals for inclusion in the proxy statement under Rule 14a-8 must be received by March 16, 2026.
- Advance notice for director nominations and other business under the Company's Bylaws must be received by March 16, 2026.
- Notice for director nominees under the SEC's universal proxy rule (Rule 14a-19) must be provided by April 10, 2026.
Tvardi Therapeutics, Inc. has released an updated corporate presentation via a Regulation FD disclosure. This filing is for informational purposes and does not contain material non-public information or significant structural changes.
📋 Key Facts
- Company released an updated corporate presentation on January 16, 2026.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
- The update was made available on the Company's website.
Tvardi Therapeutics announced the approval of one-time retention compensation for key executives and the establishment of a new Severance and Change in Control Plan. The measures are designed to incentivize leadership during ongoing clinical trials and provide protection/incentives in the event of a corporate transaction.
🚩 Red Flags
- Establishment of significant severance/change-in-control benefits often precedes M&A activity or restructuring.
- The focus on 'retention' and 'severance' suggests the company is positioning itself for a potential exit or transition in its clinical development stage.
📋 Key Facts
- Board approved retention options for CEO Dr. Imran Alibhai (47,500 shares), CMO Dr. John Kauh (17,500 shares), and CFO Dan Conn (17,500 shares).
- Retention options vest starting December 16, 2026, with 25% upfront and the remainder over 36 monthly installments.
- A new Severance and Change in Control Plan was approved for 'Eligible Employees,' including all named executive officers.
- Severance benefits include cash payments (salary-based), COBRA premiums, and equity vesting acceleration upon a 'Covered Termination'.
- The plan includes specific provisions for accelerated vesting if an acquirer fails to assume or continue outstanding unvested equity awards during a Change in Control.
Tvardi Therapeutics, Inc. has released an updated corporate presentation via Regulation FD disclosure. This is a routine informational filing intended to provide market participants with current company data.
📋 Key Facts
- Company released an updated Corporate Presentation on November 19, 2025.
- The information was furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
- The presentation is available via the Company's website as Exhibit 99.1.
Tvardi Therapeutics, Inc. filed an 8-K to announce its financial results and business highlights for the fiscal quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Fiscal quarter ended September 30, 2025
- The filing includes a press release regarding financial results and business highlights (Exhibit 99.1).
Tvardi Therapeutics, Inc. issued a press release providing an update on preliminary data from its Phase 2 REVERT Trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The filing serves as a formal disclosure of clinical trial progress via Item 8.01.
📋 Key Facts
- Company released preliminary data from the Phase 2 REVERT Trial on October 13, 2025.
- The trial focuses on Idiopathic Pulmonary Fibrosis (IPF).
- The disclosure was made under Item 8.01 (Other Events).
Tvardi Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal notification that a press release containing these results was issued on August 14, 2025.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2025.
- Announcement date: August 14, 2025.
- The company recently changed its name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. announced the resignation of Shaheen Wirk from its Board of Directors, effective July 8, 2025. The company stated the resignation was not due to any disagreement with the firm.
📋 Key Facts
- Shaheen Wirk resigned from the Board of Directors on July 8, 2025.
- The departure is explicitly noted as NOT being the result of a disagreement with the Company.
- Dr. Wirk has served as a board member since March 2024 and previously acted as a special advisor.
Tvardi Therapeutics, Inc. updated its corporate presentation as of June 6, 2025, and made it available on the company's website.
📋 Key Facts
- Company updated its corporate presentation on June 6, 2025.
- The updated presentation is intended for use in communications with analysts, investors, and other parties.
- The presentation is included as Exhibit 99.1.
Tvardi Therapeutics announced the completion of patient enrollment for its Phase 2 clinical trial of TTI-101, targeting Idiopathic Pulmonary Fibrosis (IPF). This is a regulatory/clinical milestone update via press release.
📋 Key Facts
- Completion of enrollment in Phase 2 Clinical Trial of TTI-101.
- The target indication for the trial is Idiopathic Pulmonary Fibrosis (IPF).
- Announcement made on May 27, 2025.
This 8-K/A (Amendment No. 1) provides supplemental financial information following a merger involving Tvardi Therapeutics, Inc. It includes updated Management's Discussion and Analysis (MD&A) and unaudited interim financial statements for the quarter ended March 31, 2025, related to the completed acquisition/merger.
🚩 Red Flags
- The filing is an amendment to a merger-related report, which often follows complex corporate restructuring that can lead to significant changes in capital structure or debt profiles.
📋 Key Facts
- The filing is an amendment to a previous 8-K filed on April 15, 2025.
- It updates Item 2.01 regarding the completion of a merger involving CT Convergence Merger Sub, Inc. and Tvardi Operating Company, Inc.
- Includes unaudited condensed financial statements for Private Tvardi for the quarter ended March 31, 2025 (Exhibit 99.6).
- Provides updated Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) as Exhibit 99.7.
Tvardi Therapeutics, Inc. has dismissed Ernst & Young LLP (EY) as its independent auditor and engaged Deloitte & Touche LLP for the fiscal year ending December 31, 2025. The company also released its financial results for the quarter ended March 31, 2025.
🚩 Red Flags
- Auditor change: The dismissal of a Big Four firm (EY) in favor of another (Deloitte) can sometimes signal underlying friction, though the company explicitly states no disagreements occurred.
- Multiple 8-K items: The filing contains both an auditor change (4.01) and results of operations/financial condition (2.02).
📋 Key Facts
- Dismissal of Ernst & Young LLP (EY) effective immediately following the filing of the Q1 2025 Form 10-Q.
- Engagement of Deloitte & Touche LLP as the new independent registered public accounting firm on May 13, 2025.
- The company reported no disagreements with EY regarding accounting principles, practices, or auditing procedures for fiscal years 2023, 2024, and through May 12, 2025.
- EY's previous audit reports for 2023 and 2024 did not contain adverse opinions, disclaimers of opinion, or qualifications regarding uncertainty or accounting principles.
Tvardi Therapeutics, Inc. (formerly Cara Therapeutics, Inc.) completed a merger with Tvardi on April 15, 2025, resulting in a name change and the assumption of several material license agreements. The company also entered into indemnification agreements for new officers/directors and a registration rights agreement for >5% stockholders.
🚩 Red Flags
- Registration Rights Agreement with >5% stockholders implies potential future dilution through the registration of shares held by insiders/large stakeholders.
- Significant royalty obligations (low-single-digit % of net sales) and milestone payments to Baylor College of Medicine for multiple license agreements.
📋 Key Facts
- Merger completed on April 15, 2025; Tvardi survived as a wholly owned subsidiary of Cara Therapeutics, Inc. (now renamed Tvardi Therapeutics, Inc.).
- Company name changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
- Entered into indemnification agreements with new directors and executive officers for expenses/costs related to their service.
- Executed a Registration Rights Agreement with >5% stockholders (including Shaheen Wirk, David J. Tweardy, and Wallace Hall) requiring an SEC registration statement within 45 days.
- Assumed the 'BCM First Agreement' regarding STAT3 inhibitors in oncology/non-oncology; includes milestone payments up to $2.2M and royalties on net sales.
- Assumed the 'BCM Second Agreement' regarding STAT3 inhibitors for conditions like anaphylaxis; includes milestone payments up to $1.225M and royalties on net sales.
Cara Therapeutics, Inc. has released an investor presentation regarding its previously announced merger with Tvardi Therapeutics, Inc. This filing serves to provide additional information to potential investors concerning the strategic combination and the post-combination company.
🚩 Red Flags
- The filing references risks associated with the completion of the merger, including the need for satisfaction or waiver of closing conditions.
📋 Key Facts
- The filing relates to a Merger Agreement entered into on December 17, 2024, between Cara Therapeutics and Tvardi Therapeutics.
- Tvardi will become a wholly-owned subsidiary of Cara following the merger.
- An investor presentation (Exhibit 99.1) was released to provide details regarding the merger and the post-combination entity.
- The merger involves CT Convergence Merger Sub Inc., a wholly-owned subsidiary of Cara.
Cara Therapeutics, Inc. held a Special Meeting of Stockholders where shareholders approved several critical proposals related to a merger with Tvardi Therapeutics, Inc., including the issuance of new shares and a reverse stock split.
🚩 Red Flags
- Reverse stock split (1-for-2 to 1-for-4) approved, often used to maintain Nasdaq listing compliance or consolidate share price.
- Significant dilution: The merger involves issuing >20% of existing common stock.
- Massive increase in authorized shares (from ~16.6M to 150M), indicating potential for significant future dilution.
📋 Key Facts
- Stockholders approved the merger of CT Convergence Merger Sub, Inc. (a Cara subsidiary) with Tvardi Therapeutics, Inc.
- The merger will result in a change of control of Cara Therapeutics via Nasdaq rules 5635(a) and 5635(b).
- Shareholders approved a reverse stock split within the range of 1-for-2 to 1-for-4.
- Authorized shares were increased from 16,666,667 to 150,000,000.
- The merger involves an issuance of common stock representing more than 20% of Cara's outstanding shares prior to the merger.
- Quorum was met with 49.38% of issued and outstanding shares represented at the meeting.
Cara Therapeutics is providing supplemental disclosures to its proxy statement/prospectus following the filing of two lawsuits by stockholders alleging that merger-related disclosures were materially false or misleading. The company also updated board composition details and management leadership roles in anticipation of the merger with Tvardi Therapeutics.
🚩 Red Flags
- Active securities litigation alleging material misstatements in merger proxy documents.
- Multiple shareholder demands (13) indicating significant stockholder dissatisfaction or organized opposition.
- Potential for litigation to delay, prevent, or increase the cost of the proposed merger.
📋 Key Facts
- Two lawsuits (Clark Complaint and Kent Complaint) filed in New York Supreme Court on March 5 and March 6, 2025.
- Plaintiffs allege the Form 424 prospectus omitted or misrepresented material information regarding the merger with Tvardi Therapeutics.
- Cara has received a total of 13 demands and 3 draft complaints from stockholders alleging similar disclosure issues.
- The proposed Combined Company Board will consist of seven directors: five designated by Tvardi, one by Cara (Susan Shiff), and one vacancy to be filled later.
- Sujal Shah is expected to serve as Chairman and Imran Alibhai as CEO of the combined company post-merger.
Cara Therapeutics, Inc. has entered into a definitive merger agreement to acquire Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on STAT3-targeting therapies for fibrosis-driven diseases.
🚩 Red Flags
- The filing contains cautionary language regarding the company's ability to regain compliance with Nasdaq Stockholders’ Equity Requirements.
- Risk mentioned regarding potential delisting determination and subsequent appeal processes.
📋 Key Facts
- Entered into an Agreement and Plan of Merger and Reorganization with Tvardi Therapeutics, Inc. on December 17, 2024.
- The transaction involves a merger where Tvardi will become a wholly-owned subsidiary of Cara Therapeutics.
- An investor presentation (Exhibit 99.1) was released to support the transaction and provide context for potential investors.
- A Form S-4 registration statement has been filed containing a preliminary proxy statement and prospectus regarding the merger.
Cara Therapeutics has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-12 reverse stock split. However, the company remains in non-compliance regarding stockholders' equity and has received an extension until May 19, 2025, to resolve this via a proposed merger with Tvardi Therapeutics.
🚩 Red Flags
- Ongoing non-compliance with stockholders' equity requirements.
- Risk of delisting if the merger with Tvardi does not successfully restore compliance by May 19, 2025.
- Recent history of a reverse stock split to prevent delisting (common in distressed micro-caps).
- The proposed merger will trigger higher listing requirements for both bid price and equity.
📋 Key Facts
- Regained compliance with Nasdaq Minimum Bid Price Requirement as of January 16, 2025.
- A 1-for-12 reverse stock split was executed on December 31, 2024, to address the bid price issue.
- The company is currently non-compliant with the Nasdaq Stockholders' Equity Requirement (reported $707,000 vs. required $2.5 million as of Sept 30, 2024).
- Nasdaq granted an extension until May 19, 2025, to regain equity compliance.
- The company is pursuing a merger with Tvardi Therapeutics, Inc., which will constitute a 'change of control' under Nasdaq rules.
Cara Therapeutics, Inc. has implemented a one-for-twelve (1-for-12) reverse stock split effective December 30, 2024. This action also includes a significant reduction in authorized shares from 200,000,000 to 16,666,667.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or improve share price)
- Significant reduction in authorized share count
- Potential signal of liquidity or capital structure distress common in micro-cap biotech firms
📋 Key Facts
- Reverse stock split ratio of 1-for-12 effective December 30, 2024, at 5:00 p.m. ET.
- Authorized shares reduced from 200,000,000 to 16,666,667.
- New CUSIP number for common stock is 140755 208.
- Trading on Nasdaq will resume on a split-adjusted basis on December 31, 2024.
- Fractional shares will be paid out in cash; no fractional shares will be issued.
This is an amendment to a previous 8-K filing intended to correct formatting errors in an investor presentation. The underlying transaction involves a proposed merger and asset disposition between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc.
🚩 Red Flags
- Significant net losses incurred by both Cara and Tvardi since inception.
- Requirement for additional capital to continue advancing product candidates, which may not be available on favorable terms or at all.
- Risks associated with the ability of the combined company to manage operating expenses during the merger process.
📋 Key Facts
- The filing is an Amendment No. 1 to the Form 8-K filed on December 18, 2024.
- Purpose of amendment: To correct formatting errors and omitted text in Exhibit 99.2 (Investor Presentation) during EDGAR conversion.
- Underlying transaction involves a proposed Merger and Asset Disposition with Tvardi Therapeutics, Inc.
- Cara Therapeutics entered into an Agreement and Plan of Merger and Reorganization dated December 17, 2024.
- The company also executed an Asset Purchase Agreement with Vifor Fresenius Medical Care Renal Pharma, Ltd. dated December 17, 2024.
Cara Therapeutics, Inc. has entered into a definitive merger agreement with Tvardi Therapeutics, Inc., which will result in a significant change of control and the reorganization of the company. The transaction involves a reverse stock split and an issuance of shares that requires stockholder approval.
🚩 Red Flags
- Significant dilution: Noteholders of Tvardi will own approximately 72.21% of the combined company.
- Reverse stock split is a required component of the merger terms.
- Change in control: The current equity holders of Cara will be significantly diluted, holding only ~15.25% post-merger.
- Management overhaul: Most of the existing Cara executive team and board members are expected to depart.
📋 Key Facts
- Merger Agreement signed on December 17, 2024, with Tvardi Therapeutics, Inc.
- Expected closing date is March 31, 2025.
- Tvardi holders of convertible notes ($28M principal) will convert into Cara Common Stock.
- Post-merger ownership: Cara equityholders ~15.25%, Tvardi equityholders ~12.54%, Noteholders ~72.21%.
- A reverse stock split is required as part of the merger approval process.
- Tvardi's CEO, CFO, CMO, and other executives will join the combined company's management team.
- Cara's current officers (Christopher Posner, Ryan Maynard, Scott Terrillion) are expected to cease being officers upon closing.
Cara Therapeutics received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement. The company's equity of $707,000 falls significantly below the required $2.5 million threshold.
🚩 Red Flags
- Delisting notice for failure to meet minimum stockholders' equity requirement.
- Existing Minimum Bid Price Deficiency (failure to maintain $1.00/share).
- Multiple concurrent delisting threats from Nasdaq.
- Potential for a reverse stock split to address bid price requirements.
📋 Key Facts
- Stockholders' equity as of Sept 30, 2024: $707,000 (Required minimum: $2.5 million).
- Company failed to meet alternative compliance standards regarding market value ($35M) or net income ($500k).
- Deadline to submit a plan to regain compliance is January 3, 2025.
- The company is already under a separate Minimum Bid Price Deficiency notice (Rule 5450(a)(1)) with a deadline of January 27, 2025.
- Management explicitly mentioned considering a reverse stock split to address the bid price deficiency.
Cara Therapeutics received a notice from Nasdaq granting an 180-day extension to regain compliance with the minimum bid price requirement. As part of this process, the company's listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective August 1, 2024.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price rule.
- Downgrade in listing tier (Nasdaq Global Market to Nasdaq Capital Market).
- Explicit mention of a potential reverse stock split to regain compliance, which is often dilutive or psychologically negative for micro-cap investors.
📋 Key Facts
- Nasdaq granted an extension until January 27, 2025, to meet minimum closing bid price requirements under Rule 5550(a)(2).
- The company's common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective August 1, 2024.
- To regain compliance, the stock must maintain a $1.00 minimum bid price for at least 10 consecutive business days.
- The company explicitly mentioned that a reverse stock split is one of the options being considered to resolve the deficiency.
Cara Therapeutics is implementing a streamlined operating plan to maximize shareholder value following the discontinuation of its clinical program for notalgia paresthetica (NP). This includes a massive 70% workforce reduction and an exploration of strategic alternatives.
🚩 Red Flags
- Discontinuation of a primary clinical program (KOURAGE-1 study) significantly impacts pipeline value.
- Massive workforce reduction (70%) indicates severe contraction of operations.
- Company is actively 'exploring strategic alternatives,' which often precedes sale, merger, or liquidation.
📋 Key Facts
- Discontinuation of the clinical program in notalgia paresthetica (NP) on June 12, 2024.
- Decision driven by dose-finding Part A results of the KOURAGE-1 study for oral difelikefalin.
- Workforce reduction of approximately 70% to be substantially completed by June 30, 2024.
- Anticipated $2.6 million in total charges related to the reduction in force (RIF).
- Charges expected to be recognized primarily in Q2 and Q3 of 2024.
Cara Therapeutics announced the discontinuation of its clinical program for oral difelikefalin in treating moderate-to-severe pruritus in patients with notalgia paresthetica (NP). The decision follows the KOURAGE-1 dose-finding study, which failed to demonstrate meaningful clinical benefit compared to a placebo.
🚩 Red Flags
- Failure of a clinical program leads to the discontinuation of a specific therapeutic pipeline asset.
- Negative clinical data in a Phase 2/3 setting directly impacts company valuation and R&D progress.
📋 Key Facts
- Study Name: KOURAGE-1 Part A (dose-finding Phase 2/3 study).
- Drug Candidate: Oral difelikefalin.
- Indication: Moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
- Trial Design: Randomized, double-blind, placebo-controlled; four arms (2 mg BID, 1 mg BID, 0.25 mg BID, and placebo) over 8 weeks.
- Outcome: Failed to meet the primary endpoint of ≥4-point improvement in the Itch-Numeric Rating Scale (I-NRS) at Week 8 for any dose level.
- Safety: The drug was noted as generally well tolerated with a safety profile similar to prior trials.
Cara Therapeutics held its Annual Meeting of Stockholders on June 4, 2024, where shareholders approved several key measures, including a significant increase in authorized shares and authorization for the Board to implement a reverse stock split.
🚩 Red Flags
- Approval of reverse stock split options (1:4 to 1:12) suggests potential pressure to maintain Nasdaq listing requirements or manage share price.
- Significant increase in authorized shares (doubled from 100M to 200M) provides the company with substantial capacity for future dilutive equity offerings.
📋 Key Facts
- Stockholders approved increasing authorized common stock from 100,000,000 to 200,000,000 shares (Proposal 4).
- Stockholders approved a series of alternate amendments allowing the Board to implement a reverse stock split ranging from 1:4 to 1:12 at its discretion (Proposal 5).
- Dr. Susan Shiff and Ms. Helen M. Boudreau were elected to the Board of Directors until 2027.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- Shareholders approved executive compensation on a non-binding advisory basis (Say-on-Pay).
Cara Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal mechanism to furnish the quarterly press release to the SEC.
📋 Key Facts
- The company reported financial results for the first quarter ended March 31, 2024.
- The announcement was made via a press release dated May 13, 2024.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Cara Therapeutics announced that its Chief Medical Officer, Dr. Joana Goncalves, will resign effective April 16, 2024, to pursue other opportunities. The departure is stated to be unrelated to any disagreements with the company.
🚩 Red Flags
- Loss of key executive (Chief Medical Officer) in a clinical-stage biotech company.
📋 Key Facts
- Dr. Joana Goncalves is resigning from her role as Chief Medical Officer.
- The resignation is effective April 16, 2024.
- The departure is not related to any disagreement with the Company.
- Duties will be assumed by other members of the senior management team during an orderly transition.
Cara Therapeutics, Inc. filed an 8-K to furnish its quarterly press release announcing financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- The filing is a standard disclosure of quarterly/annual financial results (Item 2.02).
- Reporting period: Fourth quarter and year ended December 31, 2023.
- Filing date: March 4, 2024.
Cara Therapeutics, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock traded below $1.00 for 30 consecutive business days.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Potential for forced transfer from Global Select Market to Capital Market
- Risk of permanent delisting if compliance is not met by July 30, 2024
📋 Key Facts
- Received notice of non-compliance with Nasdaq Listing Rule 5450(a)(1) on February 1, 2024.
- The deficiency is due to the common stock minimum bid price being below $1.00 for 30 consecutive business days.
- The company has a 180-day grace period until July 30, 2024, to regain compliance by maintaining a $1.00 bid price for at least ten consecutive business days.
- Failure to comply may result in delisting from The Nasdaq Global Select Market.
- The company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market, subject to other listing standards.
Cara Therapeutics is undergoing a strategic reprioritization that includes the termination of its Phase 3 clinical program for chronic kidney disease and a significant workforce reduction. The company will focus exclusively on its late-stage program for notalgia paresthetica.
🚩 Red Flags
- Termination of a Phase 3 clinical program (significant loss of R&D pipeline value).
- Workforce reduction/layoffs.
- Departure of the Chief Scientific Officer (CSO) during a major strategic pivot.
- Significant one-time restructuring charges expected in Q1 2024.
📋 Key Facts
- Termination of Phase 3 clinical program evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease (KICK 1 and KICK 2 trials).
- Workforce reduction to be substantially completed by January 31, 2024.
- Anticipated one-time charges of $2.5 million to $3 million in Q1 2024 related to termination benefits.
- Strategic shift to focus resources on oral difelikefalin for pruritus associated with notalgia paresthetica.
- Chief Scientific Officer and SVP of R&D, Frédérique Menzaghi, Ph.D., is departing effective February 2, 2024.
- Company expects capital resources to fund operations into 2026.